BMJ: Big Pharma Money ‘Permeates’ World’s Drug Regulatory Agencies | The Most Revolutionary Act

In all 6 countries, ‘Big Pharma’ provided bulk of drug regulator fundingThe issue of conflicts of interest between pharmaceutical regulators and “Big Pharma” is not new. Demasi referred to a 2005 example from the U.K., where the House of Commons health committee investigated the drug industry’s influence on health policy, including the Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K. equivalent of the U.S. Food and Drug Administration.

The committee expressed concern that pharma’s funding of the MHRA and similar agencies could lead them to “lose sight of the need to protect and promote public health above all else as it seeks to win fee income from the companies.”

“Nearly two decades on, little has changed,” Demasi reported. “Industry funding of drug regulators has become the international norm.”

For instance, the FDA, despite being the most highly funded of the six regulatory authorities studied, receives 65% of its funding for drug evaluation from industry user fees.

BMJ: Big Pharma Money ‘Permeates’ World’s Drug Regulatory Agencies | The Most Revolutionary Act